Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free CRMD Stock Alerts

CorMedix (CRMD) Financials

CorMedix logo
$8.36 -0.18 (-2.11%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$8.32 -0.04 (-0.44%)
As of 06/5/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CorMedix

Annual Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -21 -18 -25 -33 -27 -44 -22 -28 -30 -46 -18
Consolidated Net Income / (Loss)		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Net Income / (Loss) Continuing Operations		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Total Pre-Tax Income 		-20 -18 -25 -33 -27 -21 -27 -29 -30 -46 -19
Total Operating Income		 -8.90 -17 -25 -33 -27 -21 -27 -29 -31 -49 -22
Total Gross Profit		 -0.26 -0.11 -0.14 0.21 0.03 -0.09 0.03 0.04 0.06 0.00 40
Total Revenue		 0.19 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43
Operating Revenue		 0.19 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43
Total Cost of Revenue		 -0.45 -0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.19
Operating Cost of Revenue		 0.45 0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.19
Total Operating Expenses		 8.65 17 25 33 27 21 27 29 31 49 63
Selling, General & Admin Expense		 7.33 10 8.88 8.65 8.07 9.87 14 16 20 18 30
Marketing Expense		 - - - - - - - - - 18 29
Research & Development Expense		 1.32 6.28 16 24 19 11 13 13 11 13 3.94
Total Other Income / (Expense), net		 -12 -1.53 0.12 -0.17 0.03 -0.49 0.11 -0.02 0.34 2.62 3.03
Interest Expense		 2.46 0.00 0.00 0.01 0.00 0.79 0.03 0.02 0.03 0.03 0.04
Interest & Investment Income		 -0.09 0.06 0.13 0.11 0.03 0.32 0.12 0.01 0.33 2.68 2.58
Other Income / (Expense), net		 -9.00 -1.59 -0.01 -0.28 -0.00 -0.02 0.02 -0.02 0.04 -0.03 0.49
Income Tax Expense		 - - - - 0.00 -5.06 -5.17 -1.25 -0.59 0.00 -1.39
Basic Earnings per Share		 ($0.96) ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30)
Weighted Average Basic Shares Outstanding		 21.44M 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 40.27M 50.90M 58.87M
Diluted Earnings per Share		 ($0.96) ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) - - ($0.91) ($0.30)
Weighted Average Diluted Shares Outstanding		 21.44M 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 44.50M 50.90M 58.87M

Quarterly Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -11 -9.75 -15 -14 -14 -2.78 13 21 20 109
Consolidated Net Income / (Loss)		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Net Income / (Loss) Continuing Operations		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Total Pre-Tax Income 		-11 -11 -9.74 -15 -16 -14 -2.78 13 21 20 53
Total Operating Income		 -11 -12 -10 -16 -17 -15 -3.29 13 20 20 51
Total Gross Profit		 0.00 0.00 0.00 - -0.82 0.30 11 30 37 38 93
Total Revenue		 0.00 0.00 0.00 - 0.00 0.81 11 31 39 40 101
Operating Revenue		 0.00 0.00 0.00 - 0.00 0.81 11 31 39 40 101
Total Cost of Revenue		 0.00 0.00 0.00 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57
Operating Cost of Revenue		 0.00 0.00 0.00 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57
Total Operating Expenses		 11 12 10 16 16 16 14 17 17 18 42
Selling, General & Admin Expense		 7.61 3.75 3.74 2.58 8.71 7.56 6.58 0.77 9.69 9.50 25
Marketing Expense		 - 3.26 4.06 - 6.34 7.39 6.75 - 4.47 6.38 11
Research & Development Expense		 3.41 4.79 2.66 2.29 0.84 0.65 0.73 1.73 3.19 2.44 5.10
Total Other Income / (Expense), net		 0.45 0.53 0.72 0.91 0.84 1.15 0.51 1.03 0.52 0.81 1.23
Interest Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.95
Interest & Investment Income		 0.45 0.55 0.77 0.92 0.86 0.66 0.55 0.51 0.57 0.83 1.56
Other Income / (Expense), net		 0.01 -0.01 -0.03 0.00 -0.00 0.50 -0.03 0.53 -0.04 -0.02 0.62
Income Tax Expense		 0.00 0.00 0.00 - -1.39 0.00 0.00 - 0.00 0.52 -56
Basic Earnings per Share		 ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42
Weighted Average Basic Shares Outstanding		 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M
Diluted Earnings per Share		 - - ($0.17) - ($0.25) ($0.25) ($0.05) - $0.30 $0.28 $1.26
Weighted Average Diluted Shares Outstanding		 45.38M 54.81M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 68.98M 71.92M 86.21M
Weighted Average Basic & Diluted Shares Outstanding		 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M

Annual Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1.97 7.48 -3.75 2.32 7.24 -1.27 26 11 -10 0.45 -3.07
Net Cash From Operating Activities		 -6.32 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51
Net Cash From Continuing Operating Activities		 -6.32 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51
Net Income / (Loss) Continuing Operations		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Consolidated Net Income / (Loss)		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Depreciation Expense		 0.02 0.02 0.03 0.04 0.07 0.07 0.13 0.06 0.08 0.07 0.15
Amortization Expense		 - - - 0.00 0.00 0.31 0.03 0.12 0.12 0.13 0.30
Non-Cash Adjustments To Reconcile Net Income		 15 5.64 2.59 1.51 1.11 2.54 0.66 5.05 4.07 5.49 6.13
Changes in Operating Assets and Liabilities, net		 -0.52 0.01 -0.23 2.88 1.94 -1.54 -0.76 1.84 1.07 2.23 -39
Net Cash From Investing Activities		 -0.03 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21
Net Cash From Continuing Investing Activities		 -0.03 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21
Purchase of Property, Plant & Equipment		 -0.03 -0.02 -0.06 -0.15 -0.05 -0.04 -0.11 -1.43 -0.22 -0.33 -0.12
Purchase of Investments		 0.00 -24 0.00 -13 0.00 -14 -8.55 - -31 -77 -27
Sale and/or Maturity of Investments		 - - 11 24 1.60 2.12 16 -7.71 28 60 48
Net Cash From Financing Activities		 8.36 44 7.09 21 29 26 40 42 18 56 26
Net Cash From Continuing Financing Activities		 8.36 44 7.09 21 30 26 40 42 18 56 26
Issuance of Common Equity		 6.72 28 6.23 19 22 15 40 41 18 56 19
Other Financing Activities, net		 0.32 15 0.86 0.01 0.04 8.80 0.41 0.30 0.13 0.09 7.44
Effect of Exchange Rate Changes		 -0.05 -0.02 0.00 0.02 -0.01 -0.00 0.01 -0.01 -0.01 0.00 -0.00
Cash Interest Paid		 0.00 0.00 0.00 0.01 0.00 0.01 0.03 0.02 0.03 0.03 0.04

Quarterly Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Change in Cash & Equivalents		 -18 -5.61 34 -9.68 -8.46 -6.71 6.75 5.36 26 93 -110
Net Cash From Operating Activities		 -10 -8.57 -8.70 -11 -17 -14 -14 -5.61 20 30 31
Net Cash From Continuing Operating Activities		 -10 -8.57 -8.70 -11 -17 -14 -14 -5.75 20 30 31
Net Income / (Loss) Continuing Operations		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Consolidated Net Income / (Loss)		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.08 0.11 0.11 0.16
Amortization Expense		 0.03 0.03 0.03 0.03 0.04 0.09 0.09 0.09 0.09 0.09 3.55
Non-Cash Adjustments To Reconcile Net Income		 2.22 1.06 1.00 1.22 2.44 1.26 1.23 1.19 3.50 2.68 1.20
Changes in Operating Assets and Liabilities, net		 -2.09 1.59 -0.01 2.74 -5.35 -1.27 -12 -21 -4.62 7.29 -83
Net Cash From Investing Activities		 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.19 -20 -291
Net Cash From Continuing Investing Activities		 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.19 -20 -291
Purchase of Property, Plant & Equipment		 -0.01 -0.01 -0.01 -0.30 -0.06 -0.03 -0.01 -0.01 -0.01 -0.02 -0.51
Purchase of Investments		 -25 -17 -18 -16 -7.69 -12 -1.67 -5.29 -9.98 -28 -15
Sale and/or Maturity of Investments		 11 15 18 17 17 18 8.00 5.00 9.80 8.10 34
Net Cash From Financing Activities		 7.20 5.35 43 0.47 -0.10 1.06 14 11 6.09 83 151
Net Cash From Continuing Financing Activities		 7.20 5.35 43 0.47 -0.10 1.06 14 11 6.09 83 151
Issuance of Common Equity		 - - 43 0.43 0.00 - 12 5.51 6.76 82 0.00
Other Financing Activities, net		 7.20 -7.16 0.02 0.03 -0.10 0.05 1.71 5.78 -0.67 0.88 0.86

Annual Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 5.10 37 22 13 19 29 49 69 62 82 119
Total Current Assets		 5.04 37 22 13 19 29 48 66 60 79 115
Cash & Equivalents		 4.34 12 8.06 10 18 16 42 53 43 44 41
Short-Term Investments		 0.00 24 12 1.60 0.00 12 4.44 12 16 32 11
Accounts Receivable		 0.08 0.32 0.01 0.06 0.01 0.00 0.00 0.05 - 0.00 52
Inventories, net		 0.46 0.38 0.17 0.59 0.43 0.34 0.14 0.00 0.00 2.11 7.60
Prepaid Expenses		 0.16 0.81 1.32 0.45 0.43 0.48 1.47 0.82 0.63 1.24 3.63
Plant, Property, & Equipment, net		 0.04 0.04 0.07 0.19 0.16 0.12 0.11 1.47 1.61 1.87 1.83
Total Noncurrent Assets		 0.02 0.01 0.01 0.00 0.00 0.00 1.01 1.00 0.88 0.74 2.44
Long-Term Investments		 - - - - - - - 0.10 0.10 0.10 0.11
Noncurrent Note & Lease Receivables		 - - - - - - - - - - 0.00
Goodwill		 - - - - - - - - - - 0.00
Intangible Assets		 - - - - - - - - - 0.00 1.84
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - - 0.00
Other Noncurrent Operating Assets		 0.02 0.01 0.01 - 0.00 0.00 1.01 0.90 0.78 0.64 0.49
Total Liabilities & Shareholders' Equity		 5.10 37 22 13 19 29 49 69 62 82 119
Total Liabilities		 1.46 3.09 4.09 6.26 14 5.83 5.09 6.15 6.98 12 34
Total Current Liabilities		 1.43 3.06 4.09 6.26 7.77 5.83 4.16 5.35 6.31 11 34
Accounts Payable		 0.89 1.71 1.65 1.81 2.59 1.02 1.13 2.21 2.20 4.28 1.72
Accrued Expenses		 0.52 1.22 2.34 4.36 5.17 4.80 2.92 3.01 3.97 6.97 32
Other Current Liabilities		 - - - - - 0.00 0.11 0.12 0.13 0.15 0.17
Total Noncurrent Liabilities		 0.04 0.03 0.00 0.00 6.13 0.00 0.92 0.80 0.67 0.52 0.35
Capital Lease Obligations		 - - - - - - - - - - 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 - - - - 0.00 0.00 0.92 0.80 0.67 0.52 0.35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Total Preferred & Common Equity		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Common Stock		 80 128 137 159 184 219 262 308 330 392 424
Retained Earnings		 -76 -94 -119 -152 -179 -195 -217 -246 -275 -322 -340
Accumulated Other Comprehensive Income / (Loss)		 0.10 0.06 0.08 0.10 0.10 0.10 0.10 0.09 0.08 0.09 0.09

Quarterly Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 68 62 59 57 91 68 58 78 150 253 751
Total Current Assets		 65 60 57 55 89 63 53 73 145 248 260
Cash & Equivalents		 49 43 25 20 53 35 29 35 66 159 48
Short-Term Investments		 16 16 30 33 33 23 17 11 11 31 7.22
Accounts Receivable		 0.00 0.00 - - - - 0.21 17 55 43 159
Inventories, net		 0.00 0.00 - - - 2.32 4.01 6.65 7.49 9.63 29
Prepaid Expenses		 0.61 0.55 1.05 2.14 2.39 2.46 3.37 3.09 5.26 4.80 16
Plant, Property, & Equipment, net		 1.45 1.50 1.61 1.60 1.59 1.91 1.92 1.90 1.73 1.64 7.52
Total Noncurrent Assets		 0.94 0.91 0.84 0.81 0.78 2.71 2.62 2.53 2.99 2.90 484
Long-Term Investments		 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.11 0.11 0.11 23
Noncurrent Note & Lease Receivables		 - - - - - - - - - - 0.86
Goodwill		 - - - - - - - - - - 18
Intangible Assets		 - - - - - 2.00 1.95 1.90 1.79 1.74 390
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - - 53
Total Liabilities & Shareholders' Equity		 68 62 59 57 91 68 58 78 150 253 751
Total Liabilities		 6.01 5.76 5.31 7.98 8.23 10 12 19 35 32 377
Total Current Liabilities		 5.27 5.06 4.67 7.39 7.67 9.53 11 18 34 32 134
Short-Term Debt		 - - - - - - - - - - 0.84
Accounts Payable		 2.50 1.77 1.45 2.90 2.39 2.83 3.34 1.34 1.93 5.82 20
Accrued Expenses		 2.65 3.16 3.09 4.34 5.14 6.55 7.61 17 32 26 109
Other Current Liabilities		 0.13 0.13 0.14 0.14 0.15 0.15 0.16 0.16 0.17 0.18 3.25
Total Noncurrent Liabilities		 0.74 0.70 0.63 0.59 0.56 0.48 0.44 0.39 0.30 0.26 243
Capital Lease Obligations		 0.74 0.70 - 0.59 0.56 0.48 - - - - 2.97
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 145
Other Noncurrent Operating Liabilities		 - - 0.63 - - - 0.44 0.39 0.30 0.26 96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 62 56 54 49 83 58 46 59 115 221 374
Total Preferred & Common Equity		 62 56 54 49 83 58 46 59 115 221 374
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 62 56 54 49 83 58 46 59 115 221 374
Common Stock		 322 323 340 346 390 394 396 412 434 520 565
Retained Earnings		 -260 -267 -286 -297 -307 -336 -350 -353 -319 -299 -191
Accumulated Other Comprehensive Income / (Loss)		 0.04 0.05 0.10 0.09 0.08 0.08 0.09 0.09 0.08 0.08 0.09

Annual Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9,358.97% 11.02% 6.65% 46.95% 30.51% -34.09% -15.55% -20.19% -65.74% -100.00% 0.00%
EBITDA Growth		 -354.32% -1.91% -35.74% -34.03% 19.22% 22.95% -30.97% -8.31% -3.74% -60.58% 56.11%
EBIT Growth		 -239.09% -1.91% -35.77% -34.04% 19.09% 21.72% -29.33% -8.32% -3.83% -60.16% 55.36%
NOPAT Growth		 -81.11% -87.08% -48.68% -32.97% 18.41% 21.80% -29.57% -8.14% -4.03% -59.87% 54.34%
Net Income Growth		 -123.95% 11.08% -35.50% -33.95% 18.72% 38.75% -34.04% -28.07% -5.29% -56.02% 61.31%
EPS Growth		 -39.13% 39.58% -12.07% -33.95% 18.72% -19.21% 57.22% 0.00% 0.00% 0.00% 67.03%
Operating Cash Flow Growth		 -74.68% -98.18% -77.74% -28.39% 17.09% 36.49% -45.94% 3.70% -15.13% -57.70% -31.78%
Free Cash Flow Firm Growth		 -706.03% 10.77% -51.21% -25.99% 17.35% 2.66% -30.29% 7.30% -1.79% -57.81% -69.72%
Invested Capital Growth		 89.31% -119.25% -63.17% -96.72% -35.74% 27.80% 52.34% -25.21% -36.42% -53.29% 641.51%
Revenue Q/Q Growth		 77.93% -12.07% 41.43% -8.14% -13.31% -0.61% 0.00% 0.00% -28.98% -100.00% 240.63%
EBITDA Q/Q Growth		 -1.52% -10.00% -12.26% -13.10% 31.67% -57.50% -2.01% -6.27% -2.16% -17.41% 57.74%
EBIT Q/Q Growth		 -1.52% -9.99% -12.27% -13.09% 31.60% -55.84% -2.38% -6.44% -2.16% -17.33% 57.12%
NOPAT Q/Q Growth		 -7.88% -11.21% -11.98% -12.77% 31.60% -55.69% -2.67% -6.11% -2.03% -17.47% 56.13%
Net Income Q/Q Growth		 5.63% -9.99% -12.03% -13.00% 31.71% -82.99% -3.68% -6.43% -1.43% -16.45% 61.15%
EPS Q/Q Growth		 30.43% -87.10% -14.04% -13.00% 31.71% -19.21% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -11.48% -19.69% -14.76% -2.80% 0.32% 18.05% -10.29% 0.30% -1.19% -13.57% 9.20%
Free Cash Flow Firm Q/Q Growth		 -43.69% -17.66% -16.30% 1.77% -22.69% 23.45% -9.60% -3.14% 5.51% -13.40% -6.47%
Invested Capital Q/Q Growth		 -105.92% 5.25% 17.18% -98.16% 58.20% -24.64% 15.81% -5.16% -79.85% -101.22% 161.29%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -135.53% -51.68% -63.62% 65.09% 7.68% -31.76% 14.37% 22.00% 94.29% 0.00% 92.66%
EBITDA Margin		 -9,450.22% -8,675.05% -11,041.03% -10,070.21% -6,233.21% -7,287.37% -11,300.69% -15,335.95% -46,443.53% 0.00% -49.25%
Operating Margin		 -4,703.30% -7,925.56% -11,048.80% -9,997.39% -6,250.44% -7,416.31% -11,378.44% -15,417.51% -46,819.91% 0.00% -51.43%
EBIT Margin		 -9,458.18% -8,682.22% -11,052.45% -10,081.41% -6,250.48% -7,423.78% -11,368.54% -15,428.66% -46,763.12% 0.00% -50.30%
Profit (Net Income) Margin		 -10,806.25% -8,655.37% -10,996.46% -10,023.45% -6,242.40% -5,801.29% -9,207.70% -14,774.70% -45,409.90% 0.00% -41.24%
Tax Burden Percent		 104.56% 103.63% 100.00% 99.74% 100.00% 76.45% 80.99% 95.76% 98.07% 100.00% 92.78%
Interest Burden Percent		 109.27% 96.20% 99.49% 99.68% 99.87% 102.21% 100.00% 100.01% 99.02% 94.60% 88.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -116.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -113.25%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.64%
Return on Equity (ROE)		 10,546.51% -96.62% -95.10% -264.00% -442.46% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -166.09%
Operating Return on Assets (OROA)		 -443.91% -86.47% -83.95% -187.79% -166.45% -87.07% -69.04% -49.82% -46.70% 0.00% -21.77%
Return on Assets (ROA)		 -507.18% -86.20% -83.53% -186.71% -166.23% -68.04% -55.92% -47.71% -45.35% 0.00% -17.85%
Return on Common Equity (ROCE)		 10,595.64% -96.62% -95.10% -263.99% -442.42% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17%
Return on Equity Simple (ROE_SIMPLE)		 -562.76% -53.47% -138.33% -458.89% -543.74% -69.50% -49.81% -44.92% -53.94% -66.06% -21.18%
Net Operating Profit after Tax (NOPAT)		 -6.23 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16
NOPAT Margin		 -3,292.31% -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00%
Net Nonoperating Expense Percent (NNEP)		 -411.46% -32.73% -26.16% -61.33% -67.36% -8.60% -7.92% -13.55% -13.25% -17.85% -3.56%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -48.86% -18.49%
Cost of Revenue to Revenue		 -235.53% -151.68% 163.62% 34.91% 92.32% 131.76% 85.63% 78.00% 5.71% 0.00% 7.34%
SG&A Expenses to Revenue		 3,871.03% 4,884.39% 3,963.79% 2,627.28% 1,878.73% 3,482.59% 5,801.06% 8,561.30% 30,586.61% 0.00% 68.92%
R&D to Revenue		 696.73% 2,989.49% 7,021.40% 7,435.20% 4,379.39% 3,901.95% 5,591.75% 6,878.21% 16,327.59% 0.00% 9.07%
Operating Expenses to Revenue		 4,567.77% 7,873.88% 10,985.19% 10,062.48% 6,258.12% 7,384.55% 11,392.81% 15,439.51% 46,914.20% 0.00% 144.09%
Earnings before Interest and Taxes (EBIT)		 -18 -18 -25 -33 -27 -21 -27 -29 -31 -49 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -18 -25 -33 -27 -21 -27 -29 -30 -49 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 11.27 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.63
Price to Tangible Book Value (P/TBV)		 11.27 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.76
Price to Revenue (P/Rev)		 216.37 302.80 259.21 420.26 267.38 620.71 887.07 897.58 2,871.04 0.00 10.97
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.93
Enterprise Value to Revenue (EV/Rev)		 193.45 133.59 168.46 383.36 240.22 520.07 692.53 553.49 1,968.73 0.00 9.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 17.82 -1.06 -1.08 -1.30 -1.96 -1.41 -1.11 -1.05 -1.06 -1.08 -0.83
Leverage Ratio		 -20.79 1.12 1.14 1.41 2.66 1.69 1.16 1.11 1.11 1.15 1.30
Compound Leverage Factor		 -22.72 1.08 1.13 1.41 2.66 1.73 1.16 1.11 1.10 1.09 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.03% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.97% 100.00% 100.00% 99.99% 44.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.62 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -14.84 8.27 -1.85 -10.06 -12.34 7.43 18.12 11.40 9.34 3.17 4.94
Noncontrolling Interest Sharing Ratio		 -0.47% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.53 12.11 5.34 2.12 2.40 5.04 11.58 12.44 9.44 6.97 3.39
Quick Ratio		 3.10 11.66 4.93 1.92 2.27 4.86 11.14 12.26 9.32 6.67 3.05
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -11 -16 -21 -17 -17 -22 -20 -20 -32 -55
Operating Cash Flow to CapEx		 -24,883.15% -81,101.24% -37,915.97% -18,808.84% -48,474.35% -41,158.36% -19,502.87% -1,484.23% -11,103.54% -11,735.25% -43,735.12%
Free Cash Flow to Firm to Interest Expense		 -4.92 -2,728.80 -12,476.03 -3,667.41 -9,093.13 -21.05 -650.09 -1,255.85 -768.62 -937.74 -1,499.31
Operating Cash Flow to Interest Expense		 -2.56 -3,160.17 -16,983.52 -5,087.59 -12,653.80 -19.11 -661.16 -1,326.93 -918.60 -1,119.94 -1,390.32
Operating Cash Flow Less CapEx to Interest Expense		 -2.57 -3,164.06 -17,028.31 -5,114.64 -12,679.90 -19.16 -664.55 -1,416.33 -926.88 -1,129.48 -1,393.50
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.01 0.01 0.02 0.03 0.01 0.01 0.00 0.00 0.00 0.43
Accounts Receivable Turnover		 4.59 1.06 1.37 8.65 11.45 51.79 141.06 7.84 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 1.35 0.30 0.78 0.97 0.85 2.03 0.00 0.00 0.66
Fixed Asset Turnover		 4.88 5.30 4.17 2.57 2.48 2.00 2.05 0.24 0.04 0.00 23.54
Accounts Payable Turnover		 0.00 0.00 0.22 0.07 0.18 0.21 0.19 0.09 0.00 0.00 1.06
Days Sales Outstanding (DSO)		 79.57 343.89 266.93 42.21 31.87 7.05 2.59 46.57 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 270.41 1,207.94 470.39 375.03 429.45 179.60 0.00 0.00 555.18
Days Payable Outstanding (DPO)		 0.00 0.00 1,669.69 5,482.44 2,022.51 1,766.77 1,917.59 4,089.77 215,622.77 0.00 343.19
Cash Conversion Cycle (CCC)		 79.57 343.89 -1,132.35 -4,232.30 -1,520.25 -1,384.69 -1,485.55 -3,863.60 -215,622.77 0.00 211.99
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.71 -1.55 -2.52 -4.96 -6.74 -4.86 -2.32 -2.90 -3.96 -6.07 33
Invested Capital Turnover		 -0.05 -0.19 -0.11 -0.09 -0.07 -0.05 -0.07 -0.07 -0.02 0.00 3.24
Increase / (Decrease) in Invested Capital		 5.89 -0.84 -0.98 -2.44 -1.77 1.87 2.55 -0.58 -1.06 -2.11 39
Enterprise Value (EV)		 37 28 38 126 103 147 166 106 129 115 425
Market Capitalization		 41 64 58 138 115 176 212 171 188 191 477
Book Value per Share		 $0.16 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.44
Tangible Book Value per Share		 $0.16 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.41
Total Capital		 3.63 34 18 7.19 11 24 44 63 55 70 85
Total Debt		 0.00 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.34 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52
Capital Expenditures (CapEx)		 0.03 0.02 0.06 0.15 0.05 0.04 0.11 1.43 0.22 0.33 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.73 -1.56 -2.60 -5.15 -6.90 -4.99 -2.52 -4.47 -5.68 -8.06 29
Debt-free Net Working Capital (DFNWC)		 3.61 34 18 7.01 11 24 44 61 53 68 81
Net Working Capital (NWC)		 3.61 34 18 7.01 11 24 44 61 53 68 81
Net Nonoperating Expense (NNE)		 14 6.53 7.31 9.96 8.02 1.73 2.97 7.60 8.26 12 2.28
Net Nonoperating Obligations (NNO)		 -4.34 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.03 0.04 0.07 0.39 0.16 0.18 0.21 0.21 0.46
Debt-free, Cash-free Net Working Capital to Revenue		 -384.08% -742.33% -1,158.89% -1,563.31% -1,604.59% -1,760.62% -1,053.49% -2,343.31% -8,678.15% 0.00% 66.82%
Debt-free Net Working Capital to Revenue		 1,908.65% 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72%
Net Working Capital to Revenue		 1,908.65% 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 4.82M 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 40.27M 50.90M 58.87M
Adjusted Diluted Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 4.82M 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 44.50M 54.98M 58.87M
Adjusted Basic & Diluted Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.29M 6.27M 7.59M 11.03M 89.08M 24.15M 28.56M 37.67M 44.50M 54.98M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -6.23 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16
Normalized NOPAT Margin		 -3,292.31% -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00%
Pre Tax Income Margin		 -10,335.19% -8,352.02% -10,996.46% -10,049.50% -6,242.40% -7,587.87% -11,368.54% -15,429.47% -46,305.23% 0.00% -44.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.26 -4,602.41 -18,893.28 -5,908.67 -14,342.97 -26.70 -818.55 -1,847.76 -1,153.57 -1,428.35 -600.66
NOPAT to Interest Expense		 -2.53 -2,940.91 -13,220.93 -4,101.60 -10,040.01 -18.67 -573.48 -1,292.50 -808.48 -999.26 -429.87
EBIT Less CapEx to Interest Expense		 -7.27 -4,606.31 -18,938.07 -5,935.72 -14,369.07 -26.75 -821.94 -1,937.16 -1,161.84 -1,437.90 -603.84
NOPAT Less CapEx to Interest Expense		 -2.54 -2,944.81 -13,265.73 -4,128.65 -10,066.11 -18.72 -576.87 -1,381.90 -816.75 -1,008.80 -433.05
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -1.38% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,829.40% 778.54%
EBITDA Growth		 -56.69% -44.91% -51.68% -86.34% -51.99% -29.08% 69.31% 187.33% 221.84% 234.32% 1,836.63%
EBIT Growth		 -56.26% -44.61% -51.28% -85.77% -51.83% -29.48% 68.36% 185.94% 220.22% 231.92% 1,664.87%
NOPAT Growth		 -56.66% -43.25% -50.35% -86.77% -51.62% -29.62% 68.59% 217.94% 272.11% 277.79% 4,707.41%
Net Income Growth		 -50.23% -48.24% -42.18% -79.73% -36.90% -25.53% 71.50% 191.26% 242.71% 240.11% 4,009.63%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 70.59% 0.00% 220.00% 212.00% 2,620.00%
Operating Cash Flow Growth		 -54.11% -56.94% -45.07% -74.59% -66.54% -63.78% -56.94% 47.75% 214.02% 313.62% 326.06%
Free Cash Flow Firm Growth		 -160.70% -56.32% -19.89% -83.95% -72.13% -83.70% -174.78% -193.47% -30.28% 27.07% -909.86%
Invested Capital Growth		 2.34% -24.23% -37.01% -53.29% 87.29% 115.93% 517.02% 641.51% 15,531.26% 6,253.91% 2,279.74%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 777.11% 168.07% 27.26% 1.68% 153.28%
EBITDA Q/Q Growth		 -30.74% -7.41% 11.24% -49.49% -6.64% 8.78% 78.89% 525.33% 48.78% -2.75% 182.19%
EBIT Q/Q Growth		 -30.49% -7.39% 11.18% -49.26% -6.64% 8.41% 78.30% 505.46% 49.19% -2.79% 166.11%
NOPAT Q/Q Growth		 -31.33% -7.15% 11.33% -49.69% -6.61% 8.40% 78.52% 662.16% 55.58% -5.38% 456.76%
Net Income Q/Q Growth		 -28.73% -6.68% 13.57% -51.41% 1.95% 2.18% 80.38% 584.89% 53.32% -3.95% 447.52%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.67% 350.00%
Operating Cash Flow Q/Q Growth		 -68.87% 17.52% -1.46% -23.55% -61.09% 18.89% 2.78% 58.87% 451.53% 51.96% 2.88%
Free Cash Flow Firm Q/Q Growth		 -61.09% 0.89% 15.30% -36.02% -50.74% -5.78% -26.69% -45.28% 33.08% 40.78% -1,654.24%
Invested Capital Q/Q Growth		 51.97% -54.87% -2.42% -101.22% 96.02% 294.22% 2,580.55% 161.29% 13.44% -20.03% 903.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 22.68% 94.01% 97.80% 95.91% 95.31% 92.48%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,162.91% -27.98% 44.40% 51.91% 49.65% 55.32%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.47% -28.70% 42.12% 51.50% 49.18% 51.02%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.59% -28.99% 43.84% 51.40% 49.14% 51.63%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 49.90% 107.87%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 91.21% 100.00% 100.00% 100.00% 100.00% 97.44% 206.49%
Interest Burden Percent		 96.02% 95.39% 92.83% 94.17% 94.93% 92.48% 83.62% 100.00% 102.77% 104.21% 101.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.56% -106.49%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -53.62% 136.68% 229.55% 384.50% 142.31%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -52.90% 135.86% 228.79% 383.83% 138.11%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 49.34% -112.34% -179.78% -340.27% -38.59%
Return on Equity (ROE)		 -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -9,401.45% -407.60% -166.09% -61.83% 128.63% -82.67%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -26.67% -4.38% 18.97% 39.00% 38.47% 26.26%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -24.66% -3.66% 18.97% 40.08% 39.07% 54.86%
Return on Common Equity (ROCE)		 -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72%
Return on Equity Simple (ROE_SIMPLE)		 -61.63% -75.23% -47.83% 0.00% -86.60% -115.01% -78.60% 0.00% 14.95% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 13 20 19 106
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 42.12% 51.50% 47.92% 105.34%
Net Nonoperating Expense Percent (NNEP)		 -4.85% -5.19% -3.34% -5.60% -4.86% -7.04% -0.72% 0.83% 0.76% 0.66% 4.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -15.64% - - - 15.28% 17.52% 8.63% 28.05%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 39.03% 5.99% 3.83% 4.09% 4.69% 7.52%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 578.76% 57.44% 2.51% 24.80% 23.92% 25.29%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 49.84% 6.35% 5.62% 8.17% 6.15% 5.06%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,194.16% 122.70% 55.68% 44.42% 46.13% 41.47%
Earnings before Interest and Taxes (EBIT)		 -11 -12 -10 -16 -17 -15 -3.32 13 20 20 52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -12 -10 -16 -17 -15 -3.21 14 20 20 56
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.48 4.43 2.51 2.73 4.02 5.24 8.10 5.63 3.70 4.02 2.68
Price to Tangible Book Value (P/TBV)		 3.48 4.43 2.51 2.73 4.16 5.47 8.37 5.76 3.76 4.05 0.00
Price to Revenue (P/Rev)		 3,251.82 5,950.42 7,044.87 0.00 0.00 185.19 37.24 10.97 5.15 7.29 4.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.73 17.32 6.17
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.04% 5.77% 16.21%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 418.06 34.12 12.93 9.32 23.32 3.10
Enterprise Value to Revenue (EV/Rev)		 2,285.45 4,526.62 4,142.11 0.00 0.00 150.18 33.63 9.78 4.21 5.72 4.40
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.36 13.92 8.53
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.26 14.11 8.88
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.99 14.24 5.88
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.82 12.38
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 35.70 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01
Long-Term Debt to Equity		 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01
Financial Leverage		 -1.03 -1.05 -1.04 -1.08 -1.02 -1.03 -0.93 -0.83 -0.79 -0.89 -0.28
Leverage Ratio		 1.09 1.13 1.10 1.15 1.14 1.21 1.19 1.30 1.26 1.16 1.91
Compound Leverage Factor		 1.05 1.07 1.02 1.08 1.08 1.11 1.00 1.30 1.29 1.21 1.94
Debt to Total Capital		 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 1.01%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22%
Long-Term Debt to Total Capital		 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.79%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 98.80% 99.34% 100.00% 99.18% 100.00% 100.00% 100.00% 100.00% 100.00% 98.99%
Debt to EBITDA		 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.04
Net Debt to EBITDA		 0.00 1.37 2.08 0.00 1.07 0.00 0.00 0.00 0.00 0.00 -0.69
Long-Term Debt to EBITDA		 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.03
Debt to NOPAT		 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02
Net Debt to NOPAT		 0.00 1.95 2.96 0.00 1.52 0.00 0.00 0.00 0.00 0.00 -0.47
Long-Term Debt to NOPAT		 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02
Altman Z-Score		 14.93 9.35 11.25 4.51 7.19 4.10 9.61 5.92 6.24 16.74 1.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.15 7.39 11.61 6.97 6.65 4.79 3.96 3.39 4.21 7.82 1.94
Quick Ratio		 11.89 7.09 11.29 6.67 6.14 4.12 3.43 3.05 3.84 7.37 1.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.76 -7.69 -6.51 -8.86 -13 -14 -18 -26 -17 -10 -181
Operating Cash Flow to CapEx		 -70,390.67% -134,829.03% -84,894.78% -3,631.15% -28,235.89% -40,357.34% -139,769.68% -56,890.63% 193,932.43% 125,252.93% 6,100.85%
Free Cash Flow to Firm to Interest Expense		 -883.95 -1,314.10 -496.63 -1,351.17 -1,357.69 -2,154.45 -1,788.21 -2,597.87 -1,738.42 -1,544.21 -190.58
Operating Cash Flow to Interest Expense		 -1,184.35 -1,465.12 -663.27 -1,639.06 -1,760.07 -2,141.54 -1,364.04 -561.06 1,972.27 4,495.85 32.54
Operating Cash Flow Less CapEx to Interest Expense		 -1,186.04 -1,466.21 -664.05 -1,684.20 -1,766.30 -2,146.84 -1,365.01 -562.05 1,971.25 4,492.26 32.01
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.02 0.15 0.43 0.76 0.78 0.51
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.64 2.39
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66 0.81 0.78 0.69
Fixed Asset Turnover		 0.04 0.02 0.02 0.00 0.00 0.74 7.32 23.54 45.44 68.31 44.73
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.38 0.43 1.08 1.06 1.67 1.16 1.12
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 64.77 152.43
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 555.18 451.02 468.00 529.74
Days Payable Outstanding (DPO)		 263,507.26 525,271.11 1,867,035.68 0.00 952.68 858.02 337.83 343.19 218.86 314.16 324.68
Cash Conversion Cycle (CCC)		 -263,507.26 -525,271.11 -1,867,035.68 0.00 0.00 -858.02 -337.83 211.99 232.16 218.62 357.50
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.90 -2.94 -3.02 -6.07 -0.24 0.47 13 33 37 30 299
Invested Capital Turnover		 -0.03 -0.01 -0.01 0.00 0.00 -1.06 2.67 3.24 4.46 8.02 1.35
Increase / (Decrease) in Invested Capital		 0.05 -0.57 -0.81 -2.11 1.66 3.41 16 39 38 29 287
Enterprise Value (EV)		 132 165 123 115 175 196 429 425 347 695 928
Market Capitalization		 188 217 209 191 233 242 475 477 425 886 1,003
Book Value per Share		 $1.21 $1.08 $1.52 $1.28 $1.01 $0.80 $1.00 $1.44 $1.76 $3.25 $4.93
Tangible Book Value per Share		 $1.21 $1.08 $1.52 $1.28 $0.97 $0.77 $0.97 $1.41 $1.73 $3.22 ($0.44)
Total Capital		 54 50 84 70 58 46 59 85 115 221 378
Total Debt		 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00 0.00 0.00 3.81
Total Long-Term Debt		 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00 0.00 0.00 2.97
Net Debt		 -56 -52 -86 -76 -58 -46 -46 -52 -78 -191 -75
Capital Expenditures (CapEx)		 0.01 0.01 0.01 0.30 0.06 0.03 0.01 0.01 0.01 0.02 0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.62 -5.25 -5.28 -8.06 -4.75 -3.53 8.64 29 33 26 71
Debt-free Net Working Capital (DFNWC)		 52 47 81 68 54 42 55 81 110 216 127
Net Working Capital (NWC)		 52 47 81 68 54 42 55 81 110 216 126
Net Nonoperating Expense (NNE)		 2.86 3.01 2.42 3.79 2.77 3.44 0.48 -0.53 -0.52 -0.79 -2.54
Net Nonoperating Obligations (NNO)		 -56 -52 -86 -76 -58 -46 -46 -52 -78 -191 -75
Total Depreciation and Amortization (D&A)		 0.05 0.05 0.05 0.05 0.06 0.11 0.11 0.17 0.20 0.20 3.71
Debt-free, Cash-free Net Working Capital to Revenue		 -6,266.32% -14,377.30% -17,776.99% 0.00% 0.00% -270.06% 67.73% 66.82% 39.94% 21.10% 33.71%
Debt-free Net Working Capital to Revenue		 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 60.16%
Net Working Capital to Revenue		 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 59.76%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42
Adjusted Weighted Average Basic Shares Outstanding		 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.05) $0.00 $0.30 $0.28 $1.26
Adjusted Weighted Average Diluted Shares Outstanding		 45.38M 54.81M 54.81M 50.90M 54.96M 55.86M 58.83M 58.87M 68.98M 71.92M 86.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 9.06 14 19 36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 29.49% 36.05% 47.92% 35.71%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 51.21% 52.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1,253.97 -2,019.82 -800.46 -2,389.80 -1,698.86 -2,334.09 -331.83 1,345.46 2,007.31 2,927.18 54.80
NOPAT to Interest Expense		 -878.76 -1,412.27 -558.77 -1,672.99 -1,188.91 -1,633.71 -229.95 1,292.70 2,011.12 2,854.54 111.81
EBIT Less CapEx to Interest Expense		 -1,255.65 -2,020.90 -801.25 -2,434.94 -1,705.09 -2,339.40 -332.81 1,344.47 2,006.29 2,923.59 54.27
NOPAT Less CapEx to Interest Expense		 -880.45 -1,413.36 -559.55 -1,718.13 -1,195.15 -1,639.01 -230.93 1,291.71 2,010.10 2,850.95 111.28
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

CorMedix (NASDAQ: CRMD) has transformed dramatically over the last four years. The company moved from a pre-commercial, loss-making biotech into a much larger, revenue-generating business with strong profitability in 2025. The latest quarter shows very high revenue, solid operating income, and meaningful net income, but the balance sheet also reveals a large asset base driven by intangibles and deferred tax-related items, so investors should pay attention to sustainability and quality of earnings.

  • Revenue has exploded in 2025. Q3 2025 revenue was $100.6 million, up sharply from $39.7 million in Q2 2025 and far above the sub-$1 million levels seen in early 2024.
  • Profitability improved materially. Q3 2025 net income was $108.6 million, versus $19.8 million in Q2 2025 and losses in most of 2023 and 2024.
  • Operating margins are strong. Q3 2025 operating income was $51.3 million on $100.6 million of revenue, showing the business is scaling well at the operating level.
  • Operating cash flow is positive. Q3 2025 cash from operations was $30.9 million, which suggests the core business is generating cash despite heavy working-capital swings.
  • Liquidity remains sizeable. At Q3 2025, CorMedix held $48.5 million in cash and equivalents plus $7.2 million in short-term investments, along with $22.9 million in long-term investments.
  • Revenue and earnings improved steadily through 2025. Quarterly revenue increased from $39.1 million in Q1 to $39.7 million in Q2 and $100.6 million in Q3, while net income rose from $20.6 million to $19.8 million and then jumped to $108.6 million.
  • The company’s equity base strengthened in 2025. Total equity rose to $374.1 million in Q3 2025 from $114.9 million at Q1 2025, reflecting a much stronger capital position.
  • Accounts receivable are very large. Q3 2025 receivables were $158.6 million, which is significant relative to quarterly revenue and worth monitoring for collection timing.
  • Intangible assets dominate the asset base. Intangible assets were $390.0 million in Q3 2025, making a large portion of total assets and implying the balance sheet is heavily tied to acquired or capitalized value.
  • Q3 2025 operating cash flow was helped by financing and investment activity across the year. The company had negative net change in cash in Q3 2025 of $109.9 million, largely because of large investment movements and changes in operating assets and liabilities.
  • Working capital was a drag in Q3 2025. Changes in operating assets and liabilities reduced cash by $82.8 million, which is a reminder that earnings were not fully converting to cash in the quarter.
  • Investing cash outflow was very large in Q3 2025. Net cash from investing activities was negative $291.3 million, driven by investment purchases and portfolio reshuffling.
  • Share dilution remains a factor. Weighted average diluted shares rose from 68.9 million in Q1 2025 to 86.2 million in Q3 2025, suggesting dilution pressure for per-share results.
  • The balance sheet has meaningful leverage-like obligations and tax liabilities. Q3 2025 liabilities totaled $376.7 million, including $144.5 million of noncurrent deferred tax liabilities and $95.6 million of other noncurrent operating liabilities.
  • Historical performance was much weaker before 2025. In 2023 and much of 2024, CorMedix posted recurring quarterly losses and often negative operating cash flow, showing the recent turnaround is still relatively new.

Bottom line: CorMedix’s latest results show a company that has moved into a much stronger growth and profitability phase. The revenue surge and positive cash generation are clear positives, but investors should watch receivables, dilution, and the quality of the balance sheet as the company integrates its newer, much larger financial profile.

06/07/26 09:48 PM ETAI Generated. May Contain Errors.

CorMedix Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CorMedix's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

CorMedix's net income appears to be on an upward trend, with a most recent value of -$17.93 million in 2024, falling from -$20.45 million in 2014. The previous period was -$46.34 million in 2023. Find out what analysts predict for CorMedix in the coming months.

CorMedix's total operating income in 2024 was -$22.36 million, based on the following breakdown:
  • Total Gross Profit: $40.28 million
  • Total Operating Expenses: $62.64 million

Over the last 10 years, CorMedix's total revenue changed from $189.27 thousand in 2014 to $43.47 million in 2024, a change of 22,867.9%.

CorMedix's total liabilities were at $34.19 million at the end of 2024, a 186.9% increase from 2023, and a 2,236.4% increase since 2014.

In the past 10 years, CorMedix's cash and equivalents has ranged from $4.34 million in 2014 to $53.32 million in 2021, and is currently $40.65 million as of their latest financial filing in 2024.

Over the last 10 years, CorMedix's book value per share changed from 0.16 in 2014 to 1.44 in 2024, a change of 786.0%.


Related Companies

Financial statements for NASDAQ:CRMD last updated on 11/14/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel